Takeda's Adynovi Receives EMA Approval for Hemophilia A Treatment
Following the positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in November 2017, the European Commission (EC) has granted final marketing authorization for Adynovi (rurioctocog alfa pegol). This approval allows Takeda's Adynovi, a treatment for Hemophilia A, to be commercialized in the 28 member states of the European Union, as well as in Iceland, Liechtenstein, and Norway. This represents a significant advancement, offering patients suffering from blood coagulation factor deficiencies a new treatment option with an extended half-life (EHL), thereby expanding their choices.
Adynovi is based on a 3rd-generation recombinant Factor VIII and utilizes PEGylation technology, which chemically conjugates polyethylene glycol (PEG). This technology slows down the clearance rate of Factor VIII in the body, extending its half-life by 1.4 to 1.5 times and reducing the dosing frequency to twice weekly, maximizing patient convenience. In a Phase 3 clinical trial, the routine prophylaxis group receiving Adynovi demonstrated a statistically significant reduction in annualized bleeding rate (ABR), with a median of 1.9 bleeds per year compared to the on-demand group, thereby proving its clinical value.
The global hemophilia market is estimated at approximately $15 billion annually, and Adynovi's entry into the European market is expected to intensify competition with existing treatments. In a market where Sanofi and Sobi's Eloctate and Bayer's Jivi are already present, Takeda aims to solidify Adynovi's (marketed as Adynovate in the US) position as a global blockbuster. This is particularly important as Roche's non-factor therapy, Hemlibra, is rapidly gaining market share, and Adynovi is seen as a key asset in defending the position of traditional factor replacement therapies.
Following the final EMA approval, Takeda's next steps involve negotiating pricing with health authorities in each European country and securing reimbursement. The European market has varying healthcare systems and health technology assessment (HTA) criteria across different countries, so approval does not immediately translate into revenue growth. Takeda needs to demonstrate the cost-effectiveness of Adynovi, particularly the reduction in indirect healthcare costs due to the reduced dosing frequency, in key markets such as Germany and France. Successful reimbursement will be crucial for further expanding the annual revenue of over 64.6 billion yen.
This EMA approval for Adynovi marks a turning point for Takeda in the global hemophilia market, valued at approximately $15 billion annually, as it accelerates the transition from traditional treatments requiring three administrations per week to extended half-life (EHL) treatments with twice-weekly dosing. In the short term, based on the Phase 3 trial results, Adynovi will compete directly with Sanofi's Eloctate, highlighting its significant improvement in annualized bleeding rate (median ABR of 1.9), and drive new revenue growth in the European region. In the medium to long term, it will serve as a defensive measure to maintain the position of existing factor-based therapies against the increasing penetration of Roche's non-factor therapy, Hemlibra, and emerging gene therapies, and help sustain Takeda's hemophilia pipeline revenue of 64.6 billion yen. From a researcher and clinician perspective, Adynovi, with its Phase 3 data in pediatric and adult patients, will contribute to the refinement of standard-of-care (SOC) guidelines by providing an optimal balance between extended dosing intervals and inhibitor control.
Source: EMA (ema)